Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
about
Lost in Translation (LiT): IUPHAR Review 6Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guidelineHIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchFocus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsCurrent perspectives on HIV-1 antiretroviral drug resistanceLersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Elucidation of New Binding Interactions with the Human Tsg101 Protein Using Modified HIV-1 Gag-p6 Derived Peptide LigandsInsights into Phosphate Cooperativity and Influence of Substrate Modifications on Binding and Catalysis of Hexameric Purine Nucleoside PhosphorylasesPan-Pathway Based Interaction Profiling of FDA-Approved Nucleoside and Nucleobase Analogs with Enzymes of the Human Nucleotide MetabolismStructure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-1 Reverse TranscriptaseApproved Antiviral Drugs over the Past 50 YearsOnly slight impact of predicted replicative capacity for therapy response predictionModeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugsConjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its actionIdentifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction networkDB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOsStructural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap DynamicsA novel small-molecule inhibitor of HIV-1 entryEmerging and Neglected Infectious Diseases: Insights, Advances, and Challenges.Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds.Metabolism of novel anti-HIV agent 3-cyanomethyl-4-methyl-DCK by human liver microsomes and recombinant CYP enzymes.Oxovanadium(IV) cyclam and bicyclam complexes: potential CXCR4 receptor antagonists.Design and directed evolution of a dideoxy purine nucleoside phosphorylase.Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitorsSinglet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors.Synthesis and anti-HIV activity of 2'-deoxy-2'-fluoro-4'-C-ethynyl nucleoside analogs.SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsAn Enantioselective Synthesis of a MEM-Protected Aetheramide A DerivativeC-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors.Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.Inhibition of NF-κB activation sensitizes U937 cells to 3'-azido-3'-deoxythymidine induced apoptosisHuman immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.HIV protease inhibitors and obesityMolecular cloning, overexpression, purification, crystallization and preliminary X-ray diffraction analysis of a purine nucleoside phosphorylase from Bacillus subtilis strain 168.5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.
P2860
Q24289150-C38822D0-27F5-4F2E-A14F-9E05F408676BQ24608464-E94950B4-2B30-405D-B8DB-397B28D92E98Q26746070-CFAE975E-B836-40C3-B65D-8E3D7FDAA758Q26764925-666B4C19-3A35-4C64-A90A-1A370E6B6251Q26852626-F02F9000-EB76-4369-81F5-4AF5B7AEB7F1Q27663609-7BC59804-D1A9-43F5-B10D-83D0497659B9Q27666254-61DD0C8A-24D5-49C3-80AF-C2D6B6A05C9AQ27672664-EDA6E005-D996-4193-8D89-3F2F1EA4D170Q27679474-B01BA107-5B0B-45BB-A988-F5A81116EDA7Q27680709-33FD3419-F2EE-4109-B324-2DC8C4DDF1E7Q27755387-7956FACF-9049-446B-9C5C-FBE862E6D837Q28472749-25169E59-5824-48AC-A1B2-A992329050A7Q28478103-F836FEFD-BBAD-4B0D-8FD6-79F3F403F71CQ28485911-00408FEA-D37A-4255-936C-1313A736DF86Q28533728-7DC4E6C9-D3B6-40E9-B1D3-168CAF13A873Q28535401-084061E8-835C-4E01-B196-DFF5021A2C95Q28555090-5C5780D1-74EC-45E2-95D0-CA62461A7B50Q28606625-96457BA8-F0B9-421A-84D3-B3D96B6CAD2EQ30235317-479D3AF3-F636-458A-970A-F85C1B28E673Q30363318-05B2D0C7-5EA8-40BC-A39F-40F5B4904AD4Q33511412-11BE4EE2-FBD4-44F4-8713-59B0CBE2675EQ33566159-27C33E60-A331-41E3-980C-79120BF4713DQ33639946-FCD85C9F-37DD-42CC-B21E-39C3F1D7C994Q33967613-DDF35DD0-B667-4779-AEA6-ECF594FC6EC0Q33996952-06A37C97-2B7A-4FBB-BF09-57BDB3FEEDBAQ34039661-1F155C90-1F26-4DDE-8910-FDA5E25EA0EEQ34041566-D84EFD7A-234D-47EE-A88B-12CE354FC172Q34058234-7B2366D9-106C-46A8-A15A-4991819701EBQ34080214-D6121FC4-CD74-4179-8F20-707809D98182Q34107343-1A6CAA22-2FC4-416C-965A-AE06731AEA06Q34130519-29797A24-E7B9-4E48-9EF4-1988B5F4BB6BQ34162668-8DD9AA8E-E90B-4392-BAD0-8E3749327967Q34223771-925AD544-3309-4A4B-9CB9-6F9B35B841DBQ34507768-AB18811F-A392-48DA-BAB8-C05E8E17403EQ34561763-B61D0247-51F1-47D6-A47D-B02A1523946AQ34664366-F8F1FBA1-812A-4659-9ACB-D024A208B38AQ34792983-5C594D19-CF9F-4F82-9A7F-7987ED697F94Q34925709-9358CCDD-5EDD-47FF-B915-2580B8E2E4C9Q35000909-4047C62A-6166-49C8-9FF9-0E86DFCDD35AQ35012924-FA5A6F6A-B038-4FC0-8717-349898F0B556
P2860
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@ast
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@en
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@nl
type
label
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@ast
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@en
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@nl
prefLabel
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@ast
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@en
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@nl
P1476
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
@en
P304
P356
10.1016/J.IJANTIMICAG.2008.10.010
P577
2008-12-23T00:00:00Z